Sandbox:haytham1: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 21: | Line 21: | ||
{{familytree | | | | | |!| | | | | | | | | | | | | | | | | }} | {{familytree | | | | | |!| | | | | | | | | | | | | | | | | }} | ||
{{familytree | |,|-|-|-|+|-|-|-|.| | | | | | | | | | | | | }} | {{familytree | |,|-|-|-|+|-|-|-|.| | | | | | | | | | | | | }} | ||
{{familytree | G01 | | G02 | | G03 | | | | | | | | | | | | |G01=<div style="width: 15em; padding:1em;">'''Immunochemotherapeutic regimens for management of patients | {{familytree | G01 | | G02 | | G03 | | | | | | | | | | | | |G01=<div style="width: 15em; padding:1em;">'''Immunochemotherapeutic regimens for management of patients without chromosome 17p deletion or chromosome 11q deletion [[#Immunochemotherapeutic regimens for the management of patients without chromosome 17p deletion or chromosome 11q deletion|'''here''']]'''</div>|G02=<div style="width: 15em; padding:1em;">'''Immunochemotherapeutic regimens for management of patients with [[#Chemotherapy|chromosome 17p deletion]]'''</div>|G03=<div style="width: 15em; padding:1em;">'''Immunochemotherapeutic regimens for management of patients with [[#Chemotherapy|chromosome 11q deletion]]'''</div>}} | ||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | }} | {{familytree | | | | | | | | | |!| | | | | | | | | | | | | }} | ||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | }} | {{familytree | | | | | | | | | |!| | | | | | | | | | | | | }} | ||
| Line 31: | Line 31: | ||
{{familytree/end}} | {{familytree/end}} | ||
===Immunochemotherapeutic regimens for the management of patients without chromosome 17p deletion or chromosome 11q deletion=== | |||
===Immunochemotherapeutic regimens for management of patients without chromosome 17p deletion or chromosome 11q deletion=== | |||
Bendamustine + Rituximab | Bendamustine + Rituximab | ||
Revision as of 16:17, 16 October 2015
Initial patients evaluation | |||||||||||||||||||||||||||||||||||||||||||||||||
History Physical examination Complete blood count | |||||||||||||||||||||||||||||||||||||||||||||||||
Staging | |||||||||||||||||||||||||||||||||||||||||||||||||
Rai Staging System Binet Staging System | |||||||||||||||||||||||||||||||||||||||||||||||||
Rai stage 3-4 Binet stage B-C | Rai stage 0-2 Binet stage A | ||||||||||||||||||||||||||||||||||||||||||||||||
Evaluate patients by cumulative index illness rating scale | Patients managed by observation and close follow-up | ||||||||||||||||||||||||||||||||||||||||||||||||
Frail patients (CIRS ≥6) | Fit patients (CIRS <6) | ||||||||||||||||||||||||||||||||||||||||||||||||
Retixumab/obinutuzumab AND chlorambucil | FISH chromosomal analysis | ||||||||||||||||||||||||||||||||||||||||||||||||
Immunochemotherapeutic regimens for management of patients without chromosome 17p deletion or chromosome 11q deletion here | Immunochemotherapeutic regimens for management of patients with chromosome 17p deletion | Immunochemotherapeutic regimens for management of patients with chromosome 11q deletion | |||||||||||||||||||||||||||||||||||||||||||||||
Patients Age | |||||||||||||||||||||||||||||||||||||||||||||||||
Age <70 years | Age ≥70 years | ||||||||||||||||||||||||||||||||||||||||||||||||
Immunochemotherapeutic regimens for the management of patients without chromosome 17p deletion or chromosome 11q deletion
Bendamustine + Rituximab
Chlorambucil
Chlorambucil + PredniSONE
Cladribine
Cyclophosphamide/PredniSONE
Cyclophosphamide/PredniSONE + Rituximab
FCR (Fludarabine/Cyclophosphamide + Rituximab)
Fludarabine
FR (Fludarabine + Rituximab)
MethylPREDNISolone (Pulse)
PCR (Pentostatin/Cyclophosphamide + Rituximab)
Rituximab
Immunochemotherapeutic regimens for management of patients with chromosome 17p deletion
Alemtuzumab + Rituximab
Bendamustine + Rituximab
FCR (Fludarabine/Cyclophosphamide + Rituximab)
FR (Fludarabine + Rituximab)
HDMP (High-Dose Methylprednisolone) + Rituximab
Immunochemotherapeutic regimens for management of patients with chromosome 11q deletion
Bendamustine + Rituximab
Chlorambucil
Chlorambucil + PredniSONE
Cyclophosphamide/PredniSONE
Cyclophosphamide/PredniSONE + Rituximab
FCR (Fludarabine/Cyclophosphamide + Rituximab)
PCR (Pentostatin/Cyclophosphamide + Rituximab)
Reduced-dose FCR (Fludarabine/Cyclophosphamide + Rituximab)
Rituximab